Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,662 public trials 323 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Completed

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

NCT03748953

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Beijing Chaoyang Hospital Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
View Trial Details
Completed

REST - Replacing Steroids in the Transplant Ineligble

NCT04939844

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Zealand University Hospital Roskilde, Denmark
  • Oslo University Hospital Oslo, Norway
  • Helse Stavanger HF Stavanger, Norway
  • St. Olav University Hospital Trondheim, Norway
View Trial Details
Completed

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSD Medical Center - Encinitas Encinitas, California, United States
  • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital) La Jolla, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 37 locations
View Trial Details
Completed

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03544281

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Goodyear, Arizona, United States
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Indianapolis, Indiana, United States
View all 26 locations
View Trial Details

Related conditions